Mural Oncology Plc is a clinical-stage company developing cytokine-based immunotherapies for cancer using its protein engineering platform. Its portfolio includes Nemvaleukin alfa and a tumor-targeted split IL-12 program.
Mural Oncology plc (MURA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mural Oncology plc's actual EPS was -$1.87, beating the estimate of -$1.99 per share, resulting in a 6.14% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
